Edition:
United Kingdom

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,652.00GBp
5:04pm BST
Change (% chg)

-18.00 (-0.32%)
Prev Close
5,670.00
Open
5,670.00
Day's High
5,697.00
Day's Low
5,633.00
Volume
935,846
Avg. Vol
1,851,477
52-wk High
6,126.40
52-wk Low
4,544.50

Chart for

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 1.04
Market Cap(Mil.): £65,514.78
Shares Outstanding(Mil.): 1,265.91
Dividend: 68.90
Yield (%): --

Financials

  AZN.L Industry Sector
P/E (TTM): 22.12 30.93 32.76
EPS (TTM): 2.34 -- --
ROI: 7.86 15.07 14.61
ROE: 28.47 16.59 16.33

EU approves AstraZeneca immunotherapy drug for lung cancer

LONDON AstraZeneca's immunotherapy drug Imfinzi has been approved in Europe for use in lung cancer patients with inoperable disease that had advanced locally but not spread widely around the body, the drugmaker said on Monday.

4:37pm BST

EU approves AstraZeneca immunotherapy drug for lung cancer

LONDON, Sept 24 AstraZeneca's immunotherapy drug Imfinzi has been approved in Europe for use in lung cancer patients with inoperable disease that had advanced locally but not spread widely around the body, the drugmaker said on Monday.

4:32pm BST

AstraZeneca diabetes drug cuts heart risks in major study

LONDON AstraZeneca's diabetes drug Farxiga met a key goal in a major clinical study designed to show its heart-protecting benefits in a wide range of patients, potentially distinguishing it from rivals in a crowded marketplace.

11:30am BST

RPT-FOCUS-As China builds biotech sector, cash floods U.S. startups

SAN FRANCISCO/HONG KONG, Sept 24 For three whirlwind days in June, U.S. scientist Zhi Hong went shopping at the Boston Bio Conference to find drugs to fill the pipeline of his two-week-old drug company.

11:30am BST

UPDATE 1-AstraZeneca diabetes drug cuts heart risks in major study

* Farxiga cuts hospitalisation for heart failure and CV death

11:24am BST

As China builds biotech sector, cash floods U.S. startups

SAN FRANCISCO/HONG KONG For three whirlwind days in June, U.S. scientist Zhi Hong went shopping at the Boston Bio Conference to find drugs to fill the pipeline of his two-week-old drug company.

9:17am BST

AstraZeneca diabetes drug cuts heart risks in major study

LONDON, Sept 24 AstraZeneca said on Monday its diabetes drug Farxiga met a key goal in a major clinical study designed to show the heart-protecting benefits of the medicine.

7:50am BST

As China builds biotech sector, cash floods U.S. startups

SAN FRANCISCO/HONG KONG For three whirlwind days in June, U.S. scientist Zhi Hong went shopping at the Boston Bio Conference to find drugs to fill the pipeline of his two-week-old drug company.

2:05am BST

FOCUS-As China builds biotech sector, cash floods U.S. startups

SAN FRANCISCO/HONG KONG, Sept 24 For three whirlwind days in June, U.S. scientist Zhi Hong went shopping at the Boston Bio Conference to find drugs to fill the pipeline of his two-week-old drug company.

1:00am BST

AstraZeneca CEO warns of medicine shortages after Brexit: Sunday Times

LONDON Britain could see widespread medicine shortages if there is no deal to prevent friction at the border with the European Union after Brexit, the AstraZeneca chief executive told the Sunday Times.

23 Sep 2018

Earnings vs. Estimates